Protocol Ledger

NCT05835466 · Phase II · RECRUITING

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Interventional Phase II clinical trial protocol NCT05835466 sponsored by Icahn School of Medicine at Mount Sinai in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-24 Enrollment: 10 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05835466
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)10 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05835466
Protocol FieldVerified Registry Value
NCT IdentifierNCT05835466
Consolidated Lead SponsorIcahn School of Medicine at Mount Sinai
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment10 participants (ESTIMATED)
Registered Start Date2023-07-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Mount Sinai Health System across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI